The firm said it will develop a test for use at home and at the point of care to aid the diagnosis of syphilis and distinguish between active and past infections.

Growth for the firm's core lab and pathology lab businesses was offset by a decline in molecular diagnostics and near patient care in the first nine months of the year.

Quest has developed a multi-target molecular test for avian influenza A H5 virus that it plans to make available by the end of October.

The Houston-based firm is set to scale up its Flu/Covid test manufacturing for the current respiratory virus season.